Letter to the editor: Anti-RAS drugs and SARS-CoV-2 infection
Jingwei Bian, Rongsheng Zhao, Suodi Zhai, Zijian Li
Abstract
â¢There is no enough evidence to indicate that ACEIs and ARBs result in ACE2 upregulation.â¢The level of ACE2 expression is not completely related with the risk of COVID-19 infection.â¢There is currently no evidence that ACEI/ARB increase risk for COVID-19 infection from clinical trials.â¢It is not recommended that COVID-19 patients with hypertension or normal hypertensive patients at risk for exposure to stop using ACEI/ARB or change to other antihypertensive drugs.
Topics & Concepts
Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MedicineDownregulation and upregulation2019-20 coronavirus outbreakClinical trialPharmacologyCoronavirus InfectionsInternal medicineVirologyBiologyOutbreakInfectious disease (medical specialty)DiseaseGeneBiochemistryHormonal Regulation and HypertensionComputational Drug Discovery MethodsRenin-Angiotensin System Studies